Festo achieved solid financial results in fiscal year 2025. Following a 3.7% decline in turnover due to economic conditions, Festo is focusing 2026 on expanding its leadership in innovation and competitiveness. To this end, the company is continuing to further develop its structure and, with an R&D ratio of over 8%, is investing in the expansion of Seamless Automation with a comprehensive portfolio, seamless connectivity, and an intuitive digital experience.

Festo è un'azienda familiare indipendente e un attore globale nella tecnologia dell'automazione e nell'istruzione tecnica, con sede a Esslingen a.N. (Germania). Conta oltre 20.000 dipendenti in circa 250 sedi in tutto il mondo, con un fatturato di circa 3,33 miliardi di euro e un tasso di R&S superiore all'8%. In qualità di partner del movimento, Festo offre tecnologie di azionamento pneumatico, elettrico e digitale integrate, in tutti i settori. La sua offerta comprende inoltre soluzioni software e di intelligenza artificiale, oltre a...

The development of drugs is lengthy, complex and expensive. Approaches from organ-on-a-chip research promise to shorten the time to approval of new active ingredients. Together with experts from TU Darmstadt, Festo has developed an exhibit that demonstrates the automated production of such mini-organs: A bioprinter applies human cell material to a microfluidic chip, on which organ-like tissue then grows. Festo is combining two future technologies for the first time: SupraMotion and Diffusion Bonded Manifolds.

At Next-Gen Life Science Automation, Festo is researching new solutions for medical technology and laboratory automation. At Hannover Messe 2026, Festo and Fraunhofer IPA will be demonstrating the construction of a cassette for the process step of modifying cells in CAR-T cell therapy. Automation significantly reduces production times and costs, making customised cancer therapies faster, cheaper and available to more patients.